Ro5 is a London-based AI drug discovery company founded in 2018, specializing in computational platforms that accelerate therapeutic research. Their flagship offerings include a proprietary Biomedical Knowledge Graph—over 85 million data nodes and roughly 400 million biological relationships—and an AI Chemistry Platform that applies deep learning and cheminformatics to discover and optimize drug compounds from target identification to lead optimization. With expertise spanning bioactivity prediction, ADMET profiling, and clinical analytics, Ro5 partners with pharmaceutical firms and academic institutions to deliver AI-powered solutions for R&D workflows. Their tools have been validated in projects like identifying IRAK1 inhibitors using HydraScreen in collaboration with Strateos and contributing to approvals in diseases such as Friedreich’s Ataxia from time within acquired teams